Press Releases

VANCOUVER, Dec. 5 /PRNewswire/ - Ikue Teshigawara enjoyed true Canadian east coast experiences in Halifax and Lunenburg before carrying the flame on Cape Breton Island, Nova Scotia. Taking in the Halifax farmers market, traditional music, and a lobster feast, the future speed skating commentator for Japan's coverage of the 2010 Winter Games made the most of her time on Canada's east coast.

Video package includes footage of Ikue Teshigawara running with the flame, shopping at a market and enjoying a lobster cook and feast. Package also includes scenics of Lunenburg, Cape Spear and a montage showcasing week five of the torch relay as it passed through Nova Scotia and Newfoundland & Labrador including a visit to a Viking village.

    -------------------------------------------------------------------------
    WEB Video Preview and Download link:

    http://ctc.pathfireondemand.com/viewpackage.action?packageid=274

    TIME OF POSTING: 12:00 Eastern
    DATE OF POSTING: Saturday December 5, 2009

    All video can be viewed by clicking on the link. Broadcast quality video
    is available for download by accredited journalists. Please contact
    broadcast@newswire.ca for access.
    -------------------------------------------------------------------------

    STATIONS, FOR FURTHER INFORMATION, PLEASE CALL:

    John Parker-Jervis
    Senior Media Advisor, 2010 Media Relations
    Canadian Tourism Commission
    Tel 604 377-4358
    parker-jervis.john@ctc-cct.ca

For assistance with Broadcast On-Demand, please contact CNW at broadcast@newswire.ca or 416-863-2115.

CNW Broadcast On-Demand http://cnw.pathfireondemand.com provides free, secure and easy-to-use broadcast quality material direct from our website to accredited journalists worldwide.

This material is offered for free and unrestricted news use.

SOURCE CNW Broadcast Services

HOUSTON, Dec. 5 /PRNewswire/ -- www.BackgroundNow.com Publishes Background Checks for the Top Crime, Corruption and Fraud News.

The Most Requested Court Documents for the Week Ending, Saturday, December 5th at www.BackgroundNow.com.

    1. Federal Court Documents as to Thomas Joseph Petters $3.65 Billion Ponzi
       Scheme
    2. Court documents as to Scott W Rothstein - charges of a billion-dollar
       Ponzi scheme.
    3. Facts as to the Luis Antonio Rebutti case - sexual exploitation of a
       child.
    4. Facts in the cases against John L Cockerham, Melissa Cockerham, Carolyn
       Blake & Nyree Pettaway
    5. Information, Plea Agreement & Judgment as to James R Rosendall
    6. Indictment, Plea Agreement & Judgment as to Gary Ernest Williams
    7. Shane C. Buczek Indicted for Bank Fraud While Out on Bail for Passport
       Fraud
    8. Ryan Harris and TCNISO Charged with Developing and Distributing Cable
       Network Hacking Tools
    9. Garry Souffrant, Yvonne Souffrant, and Gamaliel Souffrant, aka Neal
       Souffrant, Indicted in Connection with a Multi-Million Dollar Money
       Laundering and Mortgage Fraud Conspiracy
    10. The Complaint Against William Arthur Sassman

About

www.BackgroundNow.com provides background checks to businesses; publishes fraud, corruption, and other criminal and civil case news; and distributes case complaints, indictments, plea agreements and other court documents to analysts, bloggers, journalists, reporters and interested readers.

Anyone can request U.S. Federal Court documents in an email, text message, telephone or Skype. Please allow 2 business hours (U.S. Central) for a response.

Contact
Lee E Hill, II
CEO
www.BackgroundNow.com
Lee.Hill@backgroundnow.com
Phone (713) 784-3232 x3
Text (281) 506-2132
Skype www.backgroundnow.com

SOURCE www.BackgroundNow.com

BOCA RATON, FL -- (MARKET WIRE) -- 12/05/09 -- DirectView Holdings, Inc. (PINKSHEETS: DIRV), a company focused on ownership and management of leading video and security technology companies, is pleased to announce that the Company has been chosen to facilitate a worldwide event for the Annual Meeting of the Iberoamerican Society for Prenatal Diagnosis and Therapy (Sociedad Iberoamericana de Diagnóstico y Tratamiento Prenatal -- SIADTP).

WHO:     University of Miami/Jackson fetal therapy expert Dr. Ruben
         Quintero, director of the Division of Maternal-Fetal Medicine,
         and more than 50 other experts from 14 different Iberoamerican
         countries.

WHAT:    World-renowned experts in fetal therapy, a field that treats
         anomalies in babies still in the womb, will gather in Miami to
         present the latest advances and innovations in the field. The
         conference features more than 50 experts from 14 Iberoamerican
         countries and 122 presentations. The conference will be
         transmitted live via the Internet by DirectView.

WHEN:    December 6-8, 2009

WHERE:   Hyatt Regency Hotel, Downtown Miami
         (400 S.E. 2nd Avenue Miami, FL 33131); and on the Internet at
         http://directviewinc.com/drquintero/siadtp.html.

WHY:     Fetal therapy is a subspecialty of high-risk obstetrics and is
         practiced by few physicians in the world. Fetal therapists use
         innovative techniques to save the lives of babies still in the
         womb. The Iberoamerican Society for Prenatal Diagnosis and Therapy
         (Sociedad Iberoamericana de Diagnóstico y Tratamiento Prenatal --
         SIADTP) aims to educate and train fetal therapy professionals
         worldwide and to this end is hosting its annual scientific meeting
         in Miami, where more than 200 attendees are expected. The meeting
         will feature world renowned experts, including pioneer Dr. Ruben
         Quintero, and will present the latest innovations in the field. To
         make this unique learning opportunity available to as many
         participants as possible, the meeting will be transmitted live by
         DirectView via Internet. Interested participants can register to
         view the meeting on the web by visiting
         http://directviewinc.com/drquintero/siadtp.html and
         www.siadtpmiami.com.

Statements contained in this news release, other than those identifying historical facts, constitute "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934 and the Safe Harbor provisions as contained in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements relating to the Company's future expectations, including but not limited to revenues and earnings, technology efficacy, strategies and plans, are subject to safe harbors protection. Actual Company results and performance may be materially different from any future results, performance, strategies, plans, or achievements that may be expressed or implied by any such forward-looking statements. The Company disclaims any obligation to update or revise any forward-looking statements

Contact:

DirectView Holdings, Inc.
Roger Ralston
888-704-8700 ext. 111
or 561-750-9777 ext. 111
www.DirectViewInc.com
IR@DirectViewInc.com
or

University of Miami / Jackson Memorial
Isabel Sanchez
(305) 243-8770
isanchez3@med.miami.edu
http://med.miami.edu/

WASHINGTON, Dec. 5 /PRNewswire-USNewswire/ --

What: Cuts for a Cause

Why: To make a difference in the fight against cancer and other terminal illnesses affecting children. All proceeds from each hair service given will be donated to St. Jude Children's Research Hospital. Guests will enjoy complimentary beverages and hors d'oeuvres, provided by Four Sisters, a delectable and savory Vietnamese restaurant in Falls Church for all guests. Hoa Lai, a DJ known for creating fun and unique mixes will be spinning some fun background music sure to get your feet tapping. If you are unable to attend and would like to make a donation to St. Jude Children's Research Hospital you can send a check to Salon Leau made out to St. Jude Children's Research Hospital.

When:                 Monday December 7th
                      11-4 p.m.

Where:                Salon Leau
                      3240 P Street NW
                      Washington DC, 20007
                      (202) 625-2220
                      www.SalonLeau.com

Who:                  Salon Leau stylists and salon owner LoAnn Lai

Media Opportunities:  Interviews with Salon Leau owner, LoAnn Lai
                      11:00-11:45 p.m.
                      3:00-3:45 p.m.

Photo Opportunities:  Photos may be taken throughout the duration
                      of the event.

SOURCE Salon Leau

NEW ORLEANS, Dec. 5 /PRNewswire-USNewswire/ -- There have been significant scientific advances in the field of blood cancers, and leading experts continue to gain a better understanding of how certain diseases progress in order to discover new treatment options and provide patients with the best care. Research presented today at the 51st Annual Meeting of the American Society of Hematology explores optimal induction therapies for managing multiple myeloma, the importance of advance care planning for improved quality of life, and a potential new first-line therapy for patients with non-Hodgkin lymphoma.

"Studies such as these are designed to improve the quality of evaluation, diagnosis, and treatment of various blood cancers," said moderator of the press conference Richard A. Van Etten, M.D., Ph.D., Director of Tufts Medical Center Cancer Center in Boston. "The results of these studies not only give hematologists a better understanding of disease progression, but also direct them to the measures that are safer and more effective in treating their patients."

This press conference will take place on Saturday, December 5, at 10:00 a.m.

A Prospective, Multicenter, Randomized Trial of Bortezomib/Melphalan/Prednisone (VMP) Versus Bortezomib/Thalidomide/Prednisone (VTP) as Induction Therapy Followed by Maintenance Treatment With Bortezomib/Thalidomide (VT) Versus Bortezomib/Prednisone (VP) in Elderly Untreated Patients With Multiple Myeloma Older Than 65 Years [Abstract #3]

Multiple myeloma is a type of blood cancer that affects white blood cells known as plasma cells and is common among the elderly. In the United States, the incidence of this disease is increasing at an alarming rate with 13,000-15,000 new cases diagnosed each year.(1) Over the last few years the treatment of elderly patients older than 65 years with multiple myeloma has changed, mainly due to the introduction of novel agents such as thalidomide, bortezomib, and lenalidomide. According to results from the Velcade as Initial Standard Therapy in Multiple Myeloma: Assessment With Melphalan and Prednisone (VISTA) trial, the combination of bortezomib, melphalan, and prednisone is significantly superior to melphalan and prednisone alone, which has been the current standard of care for multiple myeloma patients who cannot receive a stem cell transplant. However, research has not yet confirmed whether an alkylating agent (chemical compound) or an immunomodulatory therapy (drug that suppresses or stimulates the body's immune response) is the optimal partner for bortezomib. Researchers from the Spanish Myeloma Group designed a study to better determine if melphalan or thalidomide should be used as part of induction therapy (the initial treatment given to patients) in combination with bortezomib. The study showed that elderly patients were able to receive less aggressive treatment regimens of induction therapy by supplementing them with a maintenance treatment.

In order to evaluate whether the induction therapy regimen could be further optimized by decreasing toxicity while maintaining efficacy, the intensity of both treatment regimens was reduced as compared with the VISTA regimen, but supplemented with maintenance therapy. In this study, 260 patients with a median age of 75 years were randomized to receive a modified induction schedule of six cycles of bortezomib, melphalan, and prednisone (VMP) or bortezomib, thalidomide, and prednisone (VTP) as induction therapy followed by maintenance therapy with bortezomib and thalidomide (VT) or bortezomib and prednisone (VP) for up to three years.

Study results indicate that modified induction schedules for both VMP and VTP were highly effective with similar overall response rates (80 percent for VMP and 81 percent for VTP), which were determined using the European Group for Blood and Marrow Transplantation (EBMT) criteria, and complete remission rates (20 percent for VMP and 27 percent for VTP), but there was a clear difference in the toxicity profile of each group. In the VMP regimen there was a higher incidence of neutropenia (abnormally low count of white blood cells) and infections, but VTP resulted in the development of cardiac toxicity. The frequency of grade 3-4 peripheral neuropathy (PN) was 5 percent in the VMP group. Maintenance therapy with either VT or VP also markedly improved the quality of patient responses with a good safety profile, increasing complete response from 23 percent up to 42 percent, with no significant differences in response rates between the VT and VP treatment arms. In addition, both maintenance regimens resulted in an acceptable toxicity profile.

"Melphalan with prednisone has been the gold standard for the treatment of elderly multiple myeloma patients for the past 40 years, but novel combination therapies have emerged as superior options," said lead author Maria-Victoria Mateos, M.D., Ph.D., Attending Physician, Hematology Department at the Hospital Universitario de Salamanca in Spain. "In this study, we demonstrate that the combination of a reduced dosage for induction therapy followed by maintenance therapy may be a novel approach for treating this patient population."

Dr. Mateos will present this study at the Plenary Scientific Session on Sunday, December 6, at 2:30 p.m. in Hall F.

(1) Cleveland Clinic. Education: Prevalence and Incidence of Multiple Myeloma. Available at: http://my.clevelandclinic.org/myeloma/education/multiple_myeloma.aspx. Accessed November 20, 2009.

Psychological Correlates of Having Advance Care Planning in Patients With Hematological Malignancies [Abstract #72]

Advance care planning (ACP) provides patients with the opportunity to communicate with their family and health-care provider about their end-of-life choices. Patients who participate in ACP usually have a living will and a health-care proxy, a person who carries out their health-care choices in the event that they become incapable of making medical decisions. However, according to previous studies, only 50 percent of patients with blood cancers who are undergoing a high-risk procedure, such as a stem cell transplant, participate in ACP. Moreover, the group that lacked ACP had a higher mortality rate, suggesting that the group least likely to have ACP is the group most in need of it. While there is a need to increase engagement in ACP, many argue that discussing possible death with patients adds to their stress level. Researchers from the University of Nebraska Medical Center in Omaha and Fred Hutchinson Cancer Research Center in Seattle compared the psychological well-being of patients with blood cancers who did or did not have ACP to help understand how best to design interventions that may increase patient engagement in ACP.

This study analyzed data from the HEMA-COMM (Hematology Communications) study cohort, an observational study that evaluated doctor-patient communication. The study included 293 patients with blood cancers who have ACP - that is, have a designated health-care proxy and a living will - or who did not have ACP - that is, they lacked a health-care proxy or a living will, or both. The two groups were compared according to socio-demographic characteristics, diagnosis, previous treatments, patient and physician estimates of cure and life expectancy, discussions of wishes for life support, and various measures of psychosocial well-being including coping, depression/anxiety, denial, social support, and quality of life.

The study found that both patients who engage and who do not engage in ACP have similar psychosocial well-being except for patterns of coping. Patients who have ACP use more problem-focused coping patterns (e.g., taking advice, active coping, seeking moral support or discussing feelings with others, planning, and having a positive outlook) as opposed to emotion-focused coping patterns (e.g., denial, behavioral or mental disengagement, turning to religion, self-blame, and substance abuse). Problem-focused coping is defined as problem solving by doing something to alter the source of stress and predominates when a person feels that something constructive can be done to affect the outcome of events. In addition, patients with ACP were more likely to be older (56 years versus 52 years), have higher income, have leukemia or myelodysplastic syndrome, and have received prior cancer treatment. The majority of patients with ACP discussed wishes for the use of life support with family (62 percent), while only 30 percent had discussed their wishes with a physician with or without family, and just 8 percent of patients had not discussed their wishes at all.

"While advance care planning may be more relevant for someone who has a life-threatening disease, it really is important to all individuals, and we hope that more people engage in this important process," said lead author Fausto R. Loberiza Jr., M.D., Associate Professor at the University of Nebraska Medical Center. "In order to increase engagement in ACP, it is important to focus on the practical importance of ACP regardless of prognosis and de-emphasize the emotional aspects of ACP. This approach may be more appealing to our patients regardless of coping style."

Dr. Loberiza will present this study in an oral presentation on Sunday, December 6, at 5:45 p.m. in Room 393-396.

Bendamustine Plus Rituximab is Superior in Respect of Progression-Free Survival and Complete Remission Rate When Compared to CHOP Plus Rituximab as First-Line Treatment of Patients With Advanced Follicular, Indolent, and Mantle Cell Lymphomas - Final Results of a Randomized Phase III Study on StiL (Study Group indolent Lymphomas, Germany) [Abstract #405]

About half of all blood cancers are those of the lymphatic system, which are classified as either Hodgkin or non-Hodgkin lymphoma. There are many types of non-Hodgkin lymphoma, including follicular lymphoma (the second most common type) and mantle cell lymphoma (a rare and difficult-to-treat cancer). While the current standard of care for patients with non-Hodgkin lymphoma is a chemotherapy regimen called CHOP (cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisone) plus the immunotherapy rituximab, it has been linked to high toxicity rates. However, promising results have been observed in two phase II studies evaluating a new combination treatment consisting of a chemotherapy agent called bendamustine plus rituximab in patients with relapsed or refractory indolent (slow-growing) or mantle cell lymphoma. In order to further investigate the role of bendamustine and rituximab combination therapy, researchers from the German Study Group Indolent Lymphoma (StiL) initiated a multicenter, randomized, phase III study to compare the efficacy and safety of bendamustine plus rituximab versus CHOP plus rituximab as a potential first-line therapy for patients with follicular, indolent, and mantle cell lymphoma.

Five hundred forty-nine patients were randomized to receive one dose of rituximab (375 mg/m2) plus two doses of bendamustine (90 mg/m2) every 28 days or the standard CHOP regimen every 21 days for a maximum of six cycles. The types of non-Hodgkin lymphoma were equally distributed between the two treatment regimens (55 percent and 56 percent for follicular lymphoma, 18 percent and 19 percent for mantle cell lymphoma, and 27 percent and 24 percent for other indolent lymphomas, respectively). The primary objective of the study was to improve progression-free survival for patients with non-Hodgkin lymphoma.

Study results revealed that bendamustine and rituximab combination therapy significantly improved progression-free survival and complete remission rates while showing less toxicity as compared with the current standard treatment. The median progression-free survival for bendamustine and rituximab combination therapy was 54.8 months compared with 34.8 months for CHOP and rituximab combination therapy. The complete remission rate of 40.1 percent for bendamustine and rituximab combination therapy was significantly higher than the 30.8 percent achieved with CHOP and rituximab combination therapy. As predicted, a higher frequency of serious adverse events was seen with the CHOP and rituximab combination therapy, such as neutropenia (10.7 percent versus 46.5 percent) and leukocytopenia (12.1 percent versus 38.2 percent). The bendamustine and rituximab combination therapy was better tolerated by patients as evidenced by lower rates of treatment side effects such as hair loss (15 percent versus 62 percent), infectious complications (95 versus 121 patients), nerve damage (18 versus 73 patients), and episodes of inflammation in the mucous lining of the mouth (16 versus 47 patients).

"While the CHOP and rituximab combination is the current standard of care, it is frequently associated with serious adverse events and more side effects, as was further shown in this study," said lead author Mathias J. Rummel, M.D., Ph.D., Head of the Department for Hematology at the University Hospital in Giessen, Germany. "These promising results suggest that the combination of bendamustine and rituximab has the potential to become the new standard, first-line treatment option for patients with these non-Hodgkin lymphoma entities."

Dr. Rummel will present this study on Monday, December 7, at 11:00 a.m. in Room 208-210.

American Society of Hematology 51st Annual Meeting

The study authors and press program moderator will be available for interviews after the press conference or by telephone. Additional press briefings will take place throughout the meeting on new approaches in clotting disorders, preventing complications and improving outcomes in transplantation, advances in diagnosing and treating leukemia and myeloproliferative disorders, and new trends and treatment options for sickle cell disease. For the complete annual meeting program and abstracts, visit www.hematology.org/2009abstracts. Up-to-date annual meeting information can also be obtained by following ASH on Twitter at ASH_hematology.

The American Society of Hematology (www.hematology.org) is the world's largest professional society concerned with the causes and treatment of blood disorders. Its mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems, by promoting research, clinical care, education, training, and advocacy in hematology. ASH provides Blood: The Vital Connection (www.bloodthevitalconnection.org), a credible online resource addressing bleeding and clotting disorders, anemia, and cancer. The official journal of ASH is Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field, which is available weekly in print and online.

SOURCE American Society of Hematology